Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

4 of 2 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05746481Phase 2Terminated

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Role: lead

NCT07224971Phase 2Recruiting

Impact of Circadian Rhythm on Immunotherapy

Role: lead

NCT03014648Phase 2Completed

Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

Role: lead

NCT02132598Phase 2Terminated

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Role: lead

NCT02730247Phase 2Completed

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Role: lead

All 5 trials loaded